Biotech | February 26, 2026
Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Nadda underlined that India’s policy framework is aligned with this transformation
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
If approved, DTX401 would be the first treatment to address the disease at its root cause
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
